PLUS THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
(in thousands, except share and par value data)
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $8,554 | $18,120 |
| Other current assets | 1,280 | 3,697 |
| Total current assets | 9,834 | 21,817 |
| Property and equipment, net | 906 | 1,324 |
| Operating lease right-use-of assets | 202 | 248 |
| Goodwill | 372 | 372 |
| Intangible assets, net | 42 | 94 |
| Other assets | 32 | 12 |
| Total assets | $11,388 | $23,867 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $6,631 | $10,134 |
| Operating lease liability | 120 | 110 |
| Term loan obligation, current | 3,976 | 1,608 |
| Total current liabilities | 10,727 | 11,852 |
| Noncurrent operating lease liability | 85 | 141 |
| Term loan obligation | — | 3,786 |
| Deferred grant liability | 1,924 | 1,643 |
| Total liabilities | 12,736 | 17,422 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of December 31, 2023 and 2022 | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, 2,240,092 shares issued and outstanding as of December 31, 2022, respectively | 5 | 2 |
| Treasury stock (at cost, 78,559 shares as of December 31, 2023) | (126) | — |
| Additional paid-in capital | 479,274 | 473,628 |
| Accumulated deficit | (480,501) | (467,185) |
| Total stockholders’ equity (deficit) | (1,348) | 6,445 |
| Total liabilities and stockholders’ equity (deficit) | $11,388 | $23,867 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.